Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults with bronchiectasis
Macrolides probably leads to lower ≥ 1 exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults with bronchiectasis
Macrolides showed no clear difference in ≥ 1 exacerbation compared with no intervention (moderate certainty).
1 finding from 1 review
Exacerbation frequency · children with bronchiectasis
Macrolides may leads to lower exacerbation frequency compared with placebo (low certainty).
1 finding from 1 review
Severe exacerbations requiring hospitalisation over the study period · adults and children with chronic asthma
Macrolides showed no clear difference in exacerbation requiring hospitalisation Weighted mean study duration:… compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe exacerbations (requiring ED visits or systemic steroids, or both) Number of people having ≥ 1 exacerbations requiring an ED visit or systemic steroids, or both. Classification varied across studies. Weighted mean study duration: 35 weeks · adults and children with chronic asthma
Macrolides probably leads to lower severe exacerbations (requiring ED visits or systemic steroids, or… compared with placebo (moderate certainty).
1 finding from 1 review